DEPARTMENT OF UROLOGY - RESEARCH

Current Protocols

Treatment/Therapeutic Trials

  • Combined Behavioral and Drug Treatment of Overactive Bladder in Men (COBALT) HSC 20100148H
  • BRinging simple urge Incontinence DiaGnosis & treatment to providers (Bridges) HSC 200900097H
  • Extended-Stress Incontinence Surgical Treatment Efficacy Trial (E-SISTEr) HSC20029180H
  • Trial of Mid-Urethral Sling (TOMUS) HSC HSC2006176H
  • Extended- Trial of Mid-Urethral Sling (E-TOMUS) HSC 20090313H
  • Value of Urodynamic Evaluation (ValUE) HSC 20080546H
  • E2805 ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Cell Carcinoma. (HSC20060267H) Formerly: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients With Resected Renal Cell Carcinoma. E2805
  • Establishment of a Data Base of Bladder Cancer in South Texas (HSC20050173H)
  • A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride vs Placebo for Patients with Clinically Organ-Confined Prostate Cancer (HSC20070101H)
  • Establishment of a Data Base of Kidney Cancer in South Texas (HSC20070118H)
  • Personal Patient Profile-Prostate (P4): A Randomized Multi-Site Trial (HSC20070578H)
  • A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer (START) (SWOG PR.11) (OCR #07-06) (HSC20070732H)
  • Development of Reference Sample Set for Evaluation of Potential Biomarkers of Prostate Cancer Standard Reference Set: Prostate Biopsy Cohort Case-Control Blood Samples (HSC20060260H)
  • Discovery of Novel Biomarkers of Renal Cell Carcinoma (HSC20070043H)
  • SWOG/RTOG 0415: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer (056-0015-268)
  • S0337: A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine vs Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer (HSC20080025H)
  • S0421: Phase III Docetaxel and Atrasentan vs Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer (HSC20070013H)
  • Tissue Bank and Data Base for Urologic Diseases (HSC20050234H)
  • Chemotherapy After Prostatectomy (CAP) for High Risk Prostate Carcinoma: A Phase III Randomized Study (CSP #553) (HSC20060187H)
  • SABOR- San Antonio Center of Biomarkers of Risk for Prostate Cancer (990-1508-030)
  • S0000 SELECT- Selenium And Vitamin E Chemoprevention Trial (SELECT) For Prostate Cancer Phase III (only open for transfer subjects from other study sites)
  • San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR), Sponsor: National Institutes of Health
  • Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease (PREF), Sponsor: National Institutes of Health

Back to top ^